Navigation Links
MAP Pharmaceuticals Reports 2008 Fourth Quarter and Year End Financial Results
Date:3/2/2009

MOUNTAIN VIEW, Calif., March 2 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the fourth quarter and year ended December 31, 2008.

The net loss for the fourth quarter ended December 31, 2008 was $21.8 million compared with $14.9 million during the same period in 2007. The net loss for the year ended December 31, 2008 was $72.9 million compared with $40.1 million for the year ended December 31, 2007.

MAP Pharmaceuticals had $44.7 million in cash, cash equivalents and short-term investments as of December 31, 2008. Subsequent to December 31, 2008, the company received a $40 million upfront payment from AstraZeneca pursuant to the worldwide Unit Dose Budesonide, UDB, collaboration signed on December 19, 2008.

"Despite the recently announced results from our UDB clinical trial, MAP Pharmaceuticals made progress in a number of areas in 2008. Moving into 2009, we have a strong balance sheet, a robust pipeline and significant upcoming milestones, including efficacy results from our first Phase 3 clinical trial of MAP0004 for the potential treatment of migraine," said Timothy S. Nelson, President and Chief Executive Officer of MAP Pharmaceuticals.

2008 and 2009 Year to Date Key Developments

Unit Dose Budesonide

  • Initiated our first Phase 3 clinical trial of UDB, for the potential treatment of asthma in children, and completed patient enrollment. On February 23, 2009 announced top-line results indicating that this trial did not meet its primary endpoints.
  • Entered into an exclusive worldwide collaboration with AstraZeneca to develop and commercialize UDB.
  • Announced positive results from a pharmacokinetic clinical trial of UDB, demonstrating lower systemic drug exposure when compared to the currently marketed conventional nebulized budesonide.

MAP0004

  • Received a Special Protocol Assessment with the U.S. Food and Drug Administration, and initiated our first Phase 3 clinical trial of MAP0004, for the potential treatment of migraine. Completed patient enrollment in the efficacy portion of this trial. Data are expected in the first half of 2009.

Pipeline Development

  • Announced positive results from a Phase 2a clinical trial of MAP0005 for the potential treatment of asthma and chronic obstructive pulmonary disease (COPD).

Other

  • Appointed H. Ward Wolff, Executive Vice President and Chief Financial Officer of Sangamo BioSciences, Inc., and Scott R. Ward, Senior Vice President and President, Medtronic CardioVascular, to the board of directors.

Fourth Quarter and 2008 Year End Financial Results

Research and development expenses for the fourth quarter and year ended December 31, 2008 were $17.7 million and $59.3 million, respectively, compared to $13.0 million and $31.4 million, respectively, for the same periods in 2007. The increase in research and development expenses for the fourth quarter ended December 31, 2008 as compared to the same period in 2007 was primarily driven by an increase in clinical expenses to support Phase 3 clinical programs initiated in 2008 for our two lead product candidates, UDB and MAP0004, and an increase in personnel related expenses to support these clinical programs. The increase in research and development expenses for the year ended December 31, 2008 as compared to the year ended December 31, 2007 was primarily driven by an increase in clinical expenses to support Phase 3 clinical programs initiated in 2008 for UDB and MAP0004, and increases in personnel related expenses to support these clinical programs, as well as manufacturing and stock-based compensation.

Sales, general and administrative expenses for the fourth quarter and year ended December 31, 2008 were $3.7 million and $13.4 million, respectively, compared to $2.7 million and $9.6 million, respectively, for the same periods in 2007. The increase in sales, general and administrative expenses for the fourth quarter ended December 31, 2008 as compared to the same period in 2007 was primarily related to increases in professional fees, stock-based compensation and personnel related expenses. The increase in sales, general and administrative expenses for the year ended December 31, 2008 as compared to the year ended December 31, 2007 was primarily related to increases in stock-based compensation, personnel related expenses, outside services and professional fees.

MAP Pharmaceuticals had cash, cash equivalents and short-term investments as of December 31, 2008 of $44.7 million, compared to $95.0 million as of December 31, 2007. For the fourth quarter and year ended December 31, 2008, non-cash share-based compensation and depreciation was approximately $1.2 million and $5.2 million, respectively. Subsequent to December 31, 2008, the company received a $40 million upfront payment from AstraZeneca pursuant to the worldwide UDB collaboration signed on December 19, 2008.

2009 Financial Outlook

MAP Pharmaceuticals' cash, cash equivalents and short-term investments as of December 31, 2008 and the upfront payment received from AstraZeneca in February 2009 provide operating capital for at least the next twelve months, and the company currently expects its cash usage for fiscal year 2009 to be less than its cash usage for fiscal year 2008. As previously disclosed, in light of the clinical results released recently with respect to MAP Pharmaceuticals' first Phase 3 clinical trial of UDB, the company and AstraZeneca are conducting further analyses of the clinical data to determine appropriate next steps for the program. In addition, the company expects to announce clinical results from the efficacy portion of its first Phase 3 clinical trial for MAP0004 during the first half of 2009. At that time the company expects to provide updated financial guidance for 2009.

About MAP Pharmaceuticals

MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for children and adults suffering from chronic conditions that are not adequately treated by currently available medicines. The company has two product candidates in Phase 3 clinical trials. Unit Dose Budesonide is being developed in collaboration with AstraZeneca for the potential treatment of asthma in children, and MAP0004 is being developed for the potential treatment of migraine. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk, by capitalizing on their known safety, efficacy and commercialization history.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

Forward-Looking Statements

In addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to MAP Pharmaceuticals' expected cash requirements during 2009 described above. Actual results may differ materially from current expectations based on risks and uncertainties affecting the company's business, including, without limitation, risks and uncertainties relating to the following: the enrollment, conduct, completion and reporting of clinical trials as well as risks related to the failure to achieve favorable clinical outcomes and the risk that AstraZeneca may not continue its collaboration with MAP Pharmaceuticals. The reader is cautioned not to unduly rely on the forward-looking statements contained in this press release. MAP Pharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Additional information on potential factors that could affect MAP Pharmaceuticals' results and other risks and uncertainties are detailed in its Quarterly Report on Form 10-Q, filed with the SEC on November 13, 2008, and available at http://edgar.sec.gov.

                            MAP PHARMACEUTICALS, INC.
                         (a development stage enterprise)
                      CONDENSED CONSOLIDATED BALANCE SHEETS
                                  (In thousands)
                                   (Unaudited)

                                                            December  December
                                                                31,       31,
                                                               2008      2007
      ASSETS
      Current assets:
        Cash, cash equivalents and short-term investments   $44,710   $94,990
        Other current assets                                    805     1,079

      Total current assets                                   45,515    96,069
      Property and equipment, net                             5,007     4,183
      Other assets                                               28       122
      Restricted cash                                           310       321

      Total assets                                          $50,860  $100,695


      LIABILITIES AND STOCKHOLDERS' EQUITY
      Current liabilities:
        Accounts payable and accrued expenses               $17,076    $8,912
        Current portion of long-term debt                     6,348     3,820

      Total current liabilities                              23,424    12,732
      Long-term debt, less current portion                   14,229     6,357
      Other liabilities                                          60         -

      Total liabilities                                      37,713    19,089

      Total stockholders' equity                             13,147    81,606

      Total liabilities and stockholders' equity            $50,860  $100,695



                                MAP PHARMACEUTICALS, INC.
                            (a development stage enterprise)
                    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                   (In thousands, except share and per share amounts)
                                      (Unaudited)

                             Three Months Ended            Twelve Months Ended
                                December 31,                  December 31,
                             2008           2007           2008         2007
    Operating expenses:
        Research and
         development       $17,663        $13,019        $59,277      $31,362
        Sales, general and
         administrative      3,732          2,744         13,417        9,567

    Total operating
     expenses               21,395         15,763         72,694       40,929

    Loss from operations   (21,395)       (15,763)       (72,694)     (40,929)

    Other income
     (expense), net           (413)           893           (234)         869

    Net loss               (21,808)       (14,870)       (72,928)     (40,060)

        Cumulative stock
         dividend
         attributable to
         preferred
         stockholders            -              -              -       (5,575)

    Net loss
     attributable to
     common stockholders  $(21,808)      $(14,870)      $(72,928)    $(45,635)

    Net loss per share
     attributable to
     common
     stockholders,
     basic and diluted      $(1.07)        $(0.76)        $(3.58)      $(8.28)

    Weighted-average
     common shares used
     in computing net
     loss per share
     attributable to
     common
     stockholders,
     basic and diluted  20,475,587     19,535,077     20,350,367    5,509,780


'/>"/>
SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Transcept Pharmaceuticals to Present at Two Upcoming Conferences
2. Endo Pharmaceuticals Announces Extension of its Tender Offer for Shares of Indevus Pharmaceuticals
3. Alexza Pharmaceuticals Promotes Peter D. Noymer, PhD to Vice President, Product R&D
4. Alseres Pharmaceuticals, Inc. Announces $200,000 Financing
5. Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results
6. Endo Pharmaceuticals Returns Product Rights to TRANSDUR(TM)-Sufentanil to DURECT
7. Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results and Highlights
8. Arbor Pharmaceuticals Announces the Launch of XYLAREX(TM) - A New Nonantibiotic Product for the Dietary Management of Recurrent Ear Infections in Children
9. Endo Pharmaceuticals Appoints William Montague to Board of Directors
10. Access Pharmaceuticals Closes Acquisition of MacroChem Corp.
11. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/14/2016)... ... February 14, 2016 , ... ... of Heart Failure Nurses (AAHFN) is promoting healthier living with heart failure by ... of Life! Healthy Living with Heart Failure will kick-off February 14 and includes ...
(Date:2/13/2016)... ... February 13, 2016 , ... ... Voices of Recovery, the leading national organization representing the growing community of recovering ... public office to include Family Recovery in policies addressing addiction. , Although ...
(Date:2/13/2016)... ... February 13, 2016 , ... In ... states that vein visualization technology should be used to ensure patient safety when ... world, the INS Standards mandate the use of vein visualization technology in patients ...
(Date:2/13/2016)... ... , ... DDi , a Makro company, makes it ... expertise in eClinical Solutions. DDi has built its solution competency with a unique ... clients. DDi provides smarter technology for Clinical Development, Regulatory and Enterprise domains by ...
(Date:2/12/2016)... WA, and Washington, DC (PRWEB) , ... ... ... PATH and the Siemens Foundation today announced a new initiative—the Siemens Foundation-PATH ... for low-resource settings. The partnership will recruit top students from U.S. universities ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... Va. , Feb. 12, 2016   National ... Hoey , RPh, MBA issued the following statement today ... released by the Centers for Medicare & ... raised by NCPA, beneficiary advocates and others: ... raised. We are still reviewing the full CMS analysis. ...
(Date:2/12/2016)... , Feb. 12, 2016 Hypermarcas ... a cash tender offer (the "Tender Offer") to ... outstanding aggregate principal amount of its 6.500% Senior ... ISIN Nos. US44915JAA88/ USP5246AAF05) (the "Notes"). In connection ... (the "Consent Solicitation") consents (the "Consents") of the ...
(Date:2/12/2016)... -- Innophos Holdings, Inc. (NASDAQ: IPHS ), a leading international ... it will host a live conference call on Tuesday, February ... quarter and full year 2015 results. ... quarter and full year results will be issued on Monday, ... --> --> The conference call can be ...
Breaking Medicine Technology: